155 related articles for article (PubMed ID: 20004097)
21. Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Zilbershtein TM; Migulin VA; Vasilevich NI; Parkhill EQ; Glushkov AI; McGregor MJ; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4070-4. PubMed ID: 19577469
[TBL] [Abstract][Full Text] [Related]
22. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
23. Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].
Uto Y; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Ogata T; Deguchi T; Yamada M; Watanabe N; Konishi M; Kurikawa N; Takagi T; Wakimoto S; Kono K; Ohsumi J
Bioorg Med Chem Lett; 2010 Jan; 20(2):746-54. PubMed ID: 20006498
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.
Lachance N; Guiral S; Huang Z; Leclerc JP; Li CS; Oballa RM; Ramtohul YK; Wang H; Wu J; Zhang L
Bioorg Med Chem Lett; 2012 Jan; 22(1):623-7. PubMed ID: 22101133
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
[TBL] [Abstract][Full Text] [Related]
27. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
[TBL] [Abstract][Full Text] [Related]
29. 2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.
Powell DA; Ramtohul Y; Lebrun ME; Oballa R; Bhat S; Falgueyret JP; Guiral S; Huang Z; Skorey K; Tawa P; Zhang L
Bioorg Med Chem Lett; 2010 Nov; 20(22):6366-9. PubMed ID: 20933412
[TBL] [Abstract][Full Text] [Related]
30. The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
Maw GN; Stobie A; Planken S; Pryde DC; Sanderson V; Platts MY; Corless M; Stacey P; Wayman C; Van Der Graaf P; Kohl C; Coggon S; Beaumont K
Chem Biol Drug Des; 2006 Jan; 67(1):74-7. PubMed ID: 16492151
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
32. Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.
Leclerc JP; Falgueyret JP; Girardin M; Guay J; Guiral S; Huang Z; Li CS; Oballa R; Ramtohul YK; Skorey K; Tawa P; Wang H; Zhang L
Bioorg Med Chem Lett; 2011 Nov; 21(21):6505-9. PubMed ID: 21924609
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
Bioorg Med Chem; 2008 Mar; 16(6):3321-41. PubMed ID: 18155554
[TBL] [Abstract][Full Text] [Related]
34. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
35. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
36. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
[TBL] [Abstract][Full Text] [Related]
37. N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Atkinson KA; Beretta EE; Brown JA; Castrodad M; Chen Y; Cosgrove JM; Du P; Litchfield J; Makowski M; Martin K; McLellan TJ; Neagu C; Perry DA; Piotrowski DW; Steppan CM; Trilles R
Bioorg Med Chem Lett; 2011 Mar; 21(6):1621-5. PubMed ID: 21324691
[TBL] [Abstract][Full Text] [Related]
38. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.
Sun D; Wang Z; Caille S; DeGraffenreid M; Gonzalez-Lopez de Turiso F; Hungate R; Jaen JC; Jiang B; Julian LD; Kelly R; McMinn DL; Kaizerman J; Rew Y; Sudom A; Tu H; Ursu S; Walker N; Willcockson M; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2011 Jan; 21(1):405-10. PubMed ID: 21093258
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
J Med Chem; 2007 Aug; 50(16):3954-63. PubMed ID: 17608467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
